Conference Day Two - Thursday, May 16, 2024
7:30 am Check-In & Coffee
8:20 am Chair’s Welcoming Remarks
Improving Quality of Life for Patients & Adherence to Treatment for GLP-1-Based Therapeutics
8:30 am Unveiling Effective Strategies to Enhance GLP-1 Tolerability
Synopsis
- Highlighting cutting-edge treatment combinations aimed at improving tolerability to enhance patient benefit
- Exploring case studies showcasing the correlation between enhanced tolerability and improved adherence to treatment plans
- Paving the way for future improvements by generating innovative ideas to optimize tolerability in GLP-1 therapeutic interventions
9:00 am Advancing Enobosarm, An Oral Novel Selective Androgen Receptor Modulator (SARM), to Avoid Muscle Loss and Augment Fat Loss When Combined with a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Drugs for Potentially Higher Quality Weight Loss
Synopsis
- Highlighting the concerns that muscle loss caused by GLP-1 receptor agonists may be responsible for weight loss plateau, upon stopping GLP-1 RA, the fat and weight rebound regain, and may accelerate the development of frailty in at-risk older sarcopenic obese patients with potential for physical function limitations
- Presenting the 5 clinical studies of enobosarm in older patients and in patients with a cancer induced starvation-like state that provide strong scientific rationale for ongoing Phase 2b enobosarm + GLP-1 RA clinical study
- Supporting evidence that enobosarm in combination with a GLP-1 RA may potentially augment the fat reduction with higher quality total weight loss while preserving muscle and physical function
9:30 am Revealing Current Modes of Delivery for Enhanced Tolerability & Envisioning Future Strategies for Further Improvement
Synopsis
- Assessing the different modes of delivery for GLP-1 treatments
- Considering the need to improve tolerability methods for GLP-1 treatments to assess the balance between the impact of side effects versus the impact of weight loss
- Assessing the benefits and drawbacks of different modes of delivery to improve tolerability of GLP-1s to discern their effectiveness at improving patients’ quality of life
10:00 am Understanding Real-World GLP-1 Prescribing Trends Using Real-Time Data from EHRs
Synopsis
- Monitoring GLP-1 prescribing patterns and patient characteristics over time, by medication, and by FDA-labeled use
- Exploring whether pre-treatment A1c and BMI measures of clinical need have fallen over time for patients with T2D newly prescribed a GLP-1
10:30 am Morning Break & Refreshments
Elucidating the Impact of the IRA & Regulatory Challenges on Clinical Approval & Pricing to Streamline Market Access
11:30 am Understanding Safety Regulations to Stay Ahead of Possible Impacts on Development of Additional GLP-1-Based Therapeutics
Synopsis
- Reaffirming confidence in the safety of GLP-1 treatments to weigh up the possibility of further regulation on development of GLP-1 therapies
- Considering the concerns of the European Medicine Agency (EMA) regarding the mental health side effects of GLP-1s to weigh up possible risks
- Reflecting on how regulation could create new challenges in GLP-1 development and the impact this may have on commercial and clinical strategy, pricing, and reimbursement of GLP-1 therapies
12:00 pm Roundtable Discussion: Investigating the Inflation Reduction Act (IRA) to Clarify the Effect This Legislation Could Have on GLP-1s to Build Appropriate Plans for Your Pipeline
Synopsis
- Maximising understanding of the IRA to ensure you are informed regarding the timing and significance of this legislative framework
- Examining the impact of the IRA regarding GLP-1-based treatments to proactively anticipate changes that may be required
- Highlighting specific areas where this regulation could exert an impact and providing examples of how to align your GLP-1 development with any requirements
12:30 pm Lunch & Networking
Discussing Product Specialization & Patient Segmentation to Develop Strategically for a More Niche Market
1:30 pm Attaining Product Differentiation through Improved Patient Segmentation & Efficiency
Synopsis
- Understanding the differentiation in the marketplace as the treatment of obesity matures
- Focusing on market segmentation and patient phenotypes to develop suitable GLP-1s for individual patient needs
2:00 pm The Differentiation Activity of GLP1R Small Molecule Agonists Could Potentially Bring Meaningful Benefits for the Patients
Synopsis
- Examining the need for differentiated products as more GLP-1s are being developed
- Developing small molecule GLP1R agonists to meet the specific needs of the patients
- Exploring the opportunities for combinations of agonists to gain long-term health benefits
2:30 pm Afternoon Break & Networking
Focusing on Enhancing GLP-1 Durability & Assessing How Adherence to Treatment Can Impact Maintenance of Weight Loss
3:00 pm Driving Durability of GLP-1-Based Therapeutics to Improve Maintenance of Weight Loss & Considering Treatments Alongside GLP-1s
Synopsis
- Exploring the resistance of patients to taking lifelong medication and considering the need for more durable GLP-1 treatments
- Delving into the newest innovations in evolving treatments that last longer to hear about techniques such as combinations that are leading to promising results
- Considering the possibility of a shortened treatment in the future to understand what this would look like and how it would change the GLP-1 market
3:30 pm Roundtable Discussion: Navigating Improvement of Weight Loss Maintenance When Taking GLP-1s
Synopsis
- Discussing adherence to maintain weight loss in patients that may be resistant to lifelong treatment
- Exploring methods to alongside treatment with GLP-1s to ensure weight loss is maintained